메뉴 건너뛰기




Volumn 37, Issue 8, 2009, Pages 1635-1645

Disposition and metabolism of radiolabeled casopitant in humans

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CASOPITANT; DRUG METABOLITE; GSK 525060; GSK 631832; UNCLASSIFIED DRUG;

EID: 67650809068     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.026781     Document Type: Article
Times cited : (19)

References (19)
  • 1
    • 68949206506 scopus 로고    scopus 로고
    • Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron
    • doi: 10.1007/s00520-008-0572-4
    • Adams LM, Johnson B, Zhang K, Yue L, Kirby L, Lebowitz P, and Stoltz R (2009) Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer doi: 10.1007/s00520-008-0572-4.
    • (2009) Support Care Cancer
    • Adams, L.M.1    Johnson, B.2    Zhang, K.3    Yue, L.4    Kirby, L.5    Lebowitz, P.6    Stoltz, R.7
  • 2
    • 33846872438 scopus 로고    scopus 로고
    • Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)
    • Arpornwirat W, Albert I, Hansen VL, Russo MA, Ross GA, Pence CD, Bandekar RR, and Grunberg SM (2006) Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 24 (Suppl 18):8512.
    • (2006) J Clin Oncol , vol.24 , Issue.SUPPL. 18 , pp. 8512
    • Arpornwirat, W.1    Albert, I.2    Hansen, V.L.3    Russo, M.A.4    Ross, G.A.5    Pence, C.D.6    Bandekar, R.R.7    Grunberg, S.M.8
  • 3
    • 67650851656 scopus 로고    scopus 로고
    • Phase III results for the novel Neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
    • Aziz Z, Arpornwirat W, Herrstedt J, Camlett I, Piontek T, Ranganathan S, Schnyder J, Bandekar RR, Levin J, and Shaharyar A (2008) Phase III results for the novel Neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 26 (Suppl 15):20512.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 15 , pp. 20512
    • Aziz, Z.1    Arpornwirat, W.2    Herrstedt, J.3    Camlett, I.4    Piontek, T.5    Ranganathan, S.6    Schnyder, J.7    Bandekar, R.R.8    Levin, J.9    Shaharyar, A.10
  • 4
    • 24944531981 scopus 로고
    • Measurement of radioactivity in biological experiments
    • Garrett ER and Hirtz JL eds Dekker, New York
    • Botta L, Gerber H-U, and Schmid K (1985) Measurement of radioactivity in biological experiments, in Drug Fate and Metabolism, Methods and Techniques (Garrett ER and Hirtz JL eds) vol 5, pp 99-134, Dekker, New York.
    • (1985) Drug Fate and Metabolism, Methods and Techniques , vol.5 , pp. 99-134
    • Botta, L.1    Gerber, H.-U.2    Schmid, K.3
  • 5
    • 33750102850 scopus 로고    scopus 로고
    • A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: Validation and applications
    • Bruin GJ, Waldmeier F, Boernsen KO, Pfaar U, Gross G, and Zollinger M (2006) A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: validation and applications. J Chromatogr A 1133:184-194.
    • (2006) J Chromatogr A , vol.1133 , pp. 184-194
    • Bruin, G.J.1    Waldmeier, F.2    Boernsen, K.O.3    Pfaar, U.4    Gross, G.5    Zollinger, M.6
  • 6
    • 67650854766 scopus 로고    scopus 로고
    • Casopitant for preventing postoperative vomiting in patients receiving opioids: Pooled data analysis
    • Chung F, Singla N, Singla S, Grenier A, and Russo M (2006) Casopitant for preventing postoperative vomiting in patients receiving opioids: pooled data analysis. Anaesthesiology 105:A206.
    • (2006) Anaesthesiology , vol.105
    • Chung, F.1    Singla, N.2    Singla, S.3    Grenier, A.4    Russo, M.5
  • 7
    • 0027275566 scopus 로고
    • Physiological parameters in laboratory animals and humans
    • Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharmacol Res 10:1093-1095.
    • (1993) Pharmacol Res , vol.10 , pp. 1093-1095
    • Davies, B.1    Morris, T.2
  • 8
    • 79953077671 scopus 로고    scopus 로고
    • Phase III results of a novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
    • Grunberg SM, Aziz Z, Shaharyar A, Herrstedt J, Roila F, VanBelle S, Bandekar RR, Russo M, and Arpornwirat W (2008) Phase III results of a novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 26 (Suppl 15):9540.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 15 , pp. 9540
    • Grunberg, S.M.1    Aziz, Z.2    Shaharyar, A.3    Herrstedt, J.4    Roila, F.5    VanBelle, S.6    Bandekar, R.R.7    Russo, M.8    Arpornwirat, W.9
  • 9
    • 67650793699 scopus 로고    scopus 로고
    • Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
    • Herrstedt J, Grunberg S, Rolski J, Bandekar RR, Guckert ME, Camlett I, Russo MW, Aziz Z, and Thorn S (2008) Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 26 (Suppl 15):9549.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 15 , pp. 9549
    • Herrstedt, J.1    Grunberg, S.2    Rolski, J.3    Bandekar, R.R.4    Guckert, M.E.5    Camlett, I.6    Russo, M.W.7    Aziz, Z.8    Thorn, S.9
  • 10
    • 68949208670 scopus 로고    scopus 로고
    • Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
    • doi: 10.1007/s00520-008-0571-5
    • Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, and Blum R (2009) Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer doi: 10.1007/s00520-008-0571-5.
    • (2009) Support Care Cancer
    • Johnson, B.1    Adams, L.2    Lu, E.3    Zhang, K.4    Lebowitz, P.5    Lates, C.6    Blum, R.7
  • 12
    • 0029717657 scopus 로고    scopus 로고
    • High sensitivity collisional-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer
    • Morris HR, Paxton T, Dell A, Langhorne J, Berg M, Bordoli RS, Hoyes J, and Bateman RH (1996) High sensitivity collisional-activated decomposition tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass spectrometer. Rapid Commun Mass Spectrom 10:889-896.
    • (1996) Rapid Commun Mass Spectrom , vol.10 , pp. 889-896
    • Morris, H.R.1    Paxton, T.2    Dell, A.3    Langhorne, J.4    Berg, M.5    Bordoli, R.S.6    Hoyes, J.7    Bateman, R.H.8
  • 13
    • 46749132406 scopus 로고    scopus 로고
    • Casopitant, a neurokinin-1 receptor antagonist with antiemetic and antinausea activity
    • Navari RM (2008) Casopitant, a neurokinin-1 receptor antagonist with antiemetic and antinausea activity. Curr Opin Investig Drugs 9:774-785.
    • (2008) Curr Opin Investig Drugs , vol.9 , pp. 774-785
    • Navari, R.M.1
  • 14
    • 0033832991 scopus 로고    scopus 로고
    • Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics
    • Oliveira EJ and Watson DG (2000) Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed Chromatogr 14:351-372.
    • (2000) Biomed Chromatogr , vol.14 , pp. 351-372
    • Oliveira, E.J.1    Watson, D.G.2
  • 15
    • 0032952578 scopus 로고    scopus 로고
    • The use of preparative high performance liquid chromatography with tandem mass spectrometric directed fraction collection for the isolation and characterization of drug metabolites in urine by nuclear magnetic resonance spectroscopy and liquid chromatography/sequential mass spectrometry
    • Plumb RS, Ayrton J, Dear GJ, Sweatman BC, and Ismail IM (1999) The use of preparative high performance liquid chromatography with tandem mass spectrometric directed fraction collection for the isolation and characterization of drug metabolites in urine by nuclear magnetic resonance spectroscopy and liquid chromatography/sequential mass spectrometry. Rapid Commun Mass Spectrom 13:845-854.
    • (1999) Rapid Commun Mass Spectrom , vol.13 , pp. 845-854
    • Plumb, R.S.1    Ayrton, J.2    Dear, G.J.3    Sweatman, B.C.4    Ismail, I.M.5
  • 16
    • 33847081694 scopus 로고    scopus 로고
    • What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs
    • Roffey SJ, Obach RS, Gedge JI, and Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17-43.
    • (2007) Drug Metab Rev , vol.39 , pp. 17-43
    • Roffey, S.J.1    Obach, R.S.2    Gedge, J.I.3    Smith, D.A.4
  • 17
    • 33747393831 scopus 로고    scopus 로고
    • Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC)
    • Rolski J, Ramlau R, Dediu M, Russo MW, Ross GA, Mather RA, Bandekar RR, and Grunberg SM (2006) Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 24 (Suppl 18):8513.
    • (2006) J Clin Oncol , vol.24 , Issue.SUPPL. 18 , pp. 8513
    • Rolski, J.1    Ramlau, R.2    Dediu, M.3    Russo, M.W.4    Ross, G.A.5    Mather, R.A.6    Bandekar, R.R.7    Grunberg, S.M.8
  • 18
    • 67650787385 scopus 로고    scopus 로고
    • Efficacy of oral casopitant mesylate, a novel neurokinin-1 receptor antagonist, with intravenous ondansetron HCl in the prevention of postoperative nausea and vomiting (PONV) in high-risk patients
    • Singla N, Chung F, Singla S, Grenier A, Kutsogiannis D, Kett A, Pergolizzi J, and Russo M (2006) Efficacy of oral casopitant mesylate, a novel neurokinin-1 receptor antagonist, with intravenous ondansetron HCl in the prevention of postoperative nausea and vomiting (PONV) in high-risk patients. Eur J Anaesthesiol 23 (Suppl 37):A614.
    • (2006) Eur J Anaesthesiol , vol.23 , Issue.SUPPL. 37
    • Singla, N.1    Chung, F.2    Singla, S.3    Grenier, A.4    Kutsogiannis, D.5    Kett, A.6    Pergolizzi, J.7    Russo, M.8
  • 19
    • 67650854765 scopus 로고    scopus 로고
    • Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
    • Strausz J, Rolski J, Aziz Z, Guckert ME, Wright O, Bandekar RR, Thorn S, and Wissel P (2008) Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day i.v./oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol 26 (Suppl 15):20585.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 15 , pp. 20585
    • Strausz, J.1    Rolski, J.2    Aziz, Z.3    Guckert, M.E.4    Wright, O.5    Bandekar, R.R.6    Thorn, S.7    Wissel, P.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.